Related Experiment Video

Updated: Aug 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy

A M L Coluccia1, R H Gunby, C J Tartari

  • 1Oncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

Expert Opinion on Therapeutic Targets
|June 14, 2005
PubMed

Insights

Anaplastic lymphoma kinase (ALK) is a key target for treating ALK-positive lymphomas. Targeting ALK offers a promising strategy for cancer therapy with reduced side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase.
  • Aberrant ALK expression and activation occur in ~60% of CD30+ anaplastic large cell lymphomas (ALCLs) due to chromosomal translocations.
  • Targeting specific molecules is crucial for effective anticancer therapies with minimal toxicity.

Purpose of the Study:

  • To identify suitable molecular targets for cancer therapy.
  • To evaluate anaplastic lymphoma kinase (ALK) as a therapeutic target in ALK-positive lymphomas.
  • To discuss strategies for targeting ALK in cancer treatment.

Main Methods:

  • Review of literature on ALK expression and function in lymphomas.
  • Analysis of ALK's role in malignant transformation.
  • Discussion of therapeutic strategies targeting ALK signaling pathways.

Main Results:

  • Anaplastic lymphoma kinase (ALK) is selectively overexpressed in ALK-positive lymphomas.
  • ALK's direct involvement in malignant transformation makes it a viable therapeutic target.
  • Targeting ALK can lead to tumor regression.

Conclusions:

  • Anaplastic lymphoma kinase (ALK) is a validated molecular target for ALK-positive lymphomas.
  • Targeting ALK directly or indirectly via its signaling network holds promise for novel anticancer therapies.
  • This approach aims to minimize systemic toxicity while maximizing therapeutic efficacy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...